is taking semaglutide dangerous Compounded "semaglutide" not FDA-approved Higher dose of semaglutide increases

Patients with established cardiovascular disease should receive a pharmacological treatment intensification with an agent that has demonstrated benefit in cardiovascular safety studies: In patients with pre-existing atherosclerotic cardiovascular disease (ASCVD), a GLP-1 receptor agonist, or SGLT-2 inhibitor with characterized cardiovascular safety should be used

Toxicology 67(2):155164 Godfrey NF, Peter A, Simon TM, Lorber A (1982) IV N-acetylcysteine treatment of hematologic reactions to chrysotherapy

However, its increasing off-label use for rapid weight loss has brought attention to its unintended effects on facial esthetics and skin health

This method is a minimally invasive option for people looking to contour their bodies without significant surgery

Losing weight already increases the risk of gallstones, and GLP-1s seem to increase it even further